Squarepoint
XLO icon

Squarepoint’s Xilio Therapeutics XLO Stock Holding History

Squarepoint’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-23,485
Closed -$277K – 4985
2025
Q3 		$277K Buy
23,485
+6,667
+40% +$66.8K ﹤0.01% 3737
2025
Q2 		$160K Buy
+16,818
New +$178K ﹤0.01% 4046

Other funds holding XLO

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return

Squarepoint's XLO Position: Q4 2025 in Review

Squarepoint sold out of Xilio Therapeutics (XLO) in Q4 2025, closing a stake of 23,485 shares — an estimated $277K sold.

Squarepoint first reported a position in XLO in Q2 2025 and held it in 2 quarters. The position peaked at $277K in Q3 2025. 37 funds tracked by Wall St. Rank hold XLO as of Q4 2025.

  • Squarepoint reported no remaining Xilio Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Squarepoint sold 23,485 Xilio Therapeutics shares in Q4 2025, an estimated $277K.
  • Squarepoint first reported a position in Xilio Therapeutics in Q2 2025 and held it in 2 quarters.
  • Squarepoint's Xilio Therapeutics position peaked at $277K in Q3 2025.
  • 37 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.